Lexaria BioscienceLEXX
LEXX
About: Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
Employees: 7
0
Funds holding %
of 7,363 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
1.43% more ownership
Funds ownership: 6.75% [Q3] → 8.17% (+1.43%) [Q4]
7% less funds holding
Funds holding: 27 [Q3] → 25 (-2) [Q4]
7% less capital invested
Capital invested by funds: $3.25M [Q3] → $3.01M (-$243K) [Q4]
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$7
393%
upside
Avg. target
$7
393%
upside
High target
$7
393%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen 41% 1-year accuracy 65 / 159 met price target | 393%upside $7 | Buy Maintained | 24 Jan 2025 |
Financial journalist opinion
Based on 8 articles about LEXX published over the past 30 days
Neutral
TheNewswire
1 week ago
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
Lexaria executing a triple-pronged strategy in obesity and diabetes Semaglutide recently approved to treat chronic kidney disease
Neutral
Accesswire
1 week ago
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
Lexaria executing a triple-pronged strategy in obesity and diabetes Semaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") strategic update. Lexaria is rapidly executing its multi-faceted strategy centered around its proprietary DehydraTECH processing technology.
Neutral
Accesswire
2 weeks ago
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
5th study arm in 12-week Phase 1b Study receives lead clinical site approval KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has received lead clinical site human research ethics committee ("HREC") approval that was required before dosing can begin in the 5th study arm of the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study") in Australia. This news complements similar news issued on November 13, 2024, when initial lead clinical site HREC approval was received for the first 4 arms of the Study.
Neutral
TheNewswire
2 weeks ago
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
5 th study arm in 12-week Phase 1b Study receives lead clinical site approval Kelowna, British Columbia – February 24, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces it has received lead clinical site human research ethics committee (“HREC” ) approval that was required before dosing can begin in the 5 th study arm of the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the “ Study ”) in Australia.
Neutral
TheNewswire
2 weeks ago
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Pursuing the world's first-ever orally-dosed liraglutide Kelowna, British Columbia – February 20, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has made a strategic business decision to further investigate the commercial opportunities and applications for a unique new GLP-1 solution: orally taken liraglutide processed with our wholly-owned DehydraTECH™ enhancement technology.
Neutral
Accesswire
2 weeks ago
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Pursuing the world's first-ever orally-dosed liraglutide KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has made a strategic business decision to further investigate the commercial opportunities and applications for a unique new GLP-1 solution: orally taken liraglutide processed with our wholly-owned DehydraTECH™ enhancement technology. "Our ability to work with liraglutide, which went off-patent last year, is an opportunity that does not often present itself," said Rich Christopher, CEO of Lexaria.
Neutral
Accesswire
4 weeks ago
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Additions broaden DehydraTECH patent suite for Epilepsy KELOWNA, BC / ACCESS Newswire / February 11, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that we have been granted two new patents from the United States Patent and Trademark Office for the use of DehydraTECH™ enhanced processing technology related to the treatment of epilepsy. "We are thrilled to have received broadened claims related to our proprietary DehydraTECH™ technology for the treatment of epilepsy," said Rich Christopher, CEO of Lexaria.
Neutral
TheNewswire
4 weeks ago
Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Additions broaden DehydraTECH patent suite for Epilepsy Kelowna, British Columbia – TheNewswire - February 11, 2025 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce that we have been granted two new patents from the United States Patent and Trademark Office for the use of DehydraTECH™ enhanced processing technology related to the treatment of epilepsy.
Neutral
Accesswire
1 month ago
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BC / ACCESS Newswire / February 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide ("FTS") rodent biodistribution study (the "Study"). Distribution of a drug once it enters the body can provide vital clues as to the understanding of that drug's ability to bind with targeted receptor cells, avoid concentration at physical sites that might be prone to fostering adverse side effects, and increase the drug's ultimate efficacy.
Neutral
TheNewswire
1 month ago
Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway
World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules Kelowna, British Columbia – February 6, 2024 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide (“ FTS ”) rodent biodistribution study (the “ Study ”).
Charts implemented using Lightweight Charts™